Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suryatheja Ananthula

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|February 26, 2021
Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated PeptidesMontserrat Puig, Suryatheja Ananthula, Ramesh Venna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|February 26, 2021
Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated PeptidesMontserrat Puig, Suryatheja Ananthula, Ramesh Venna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Pageof 2